Search
telaprevir (Incivek)
Indications:
- chronic hepatitis C genotype 1
- may be used with peginterferon alfa & ribavirin [2] (Incivek combination treatment)
Dosage:
- PO TID with food
- used in comination with peginterferon alfa & ribavirin for 1st 12 weeks of therapy [2]
Adverse effects:
- rash, can be serious, may require stopping treatment [2]
- anemia
- nausea
- fatigue
- diarrhea
- pruritus
- rectal itching, rectal pain
Drug interactions:
- serious skin reactions, some fatal, in combination with peginterferon alfa & ribavirin (Incivek combination treatment) [5]
Mechanism of action:
- protease inhibitor
- efficacy against HCV type-1
General
antiviral protease inhibitor
Database Correlations
PUBCHEM correlations
References
- McHutchison JG et al
Telaprevir with peginterferon and ribavirin for chronic
HCV genotype 1 infection.
N Engl J Med 2009 Apr 30; 360:1827
PMID: 19403902
- Hezode C et al. Telaprevir and peginterferon with or without
ribavirin for chronic HCV infection.
N Engl J Med 2009 Apr 30; 360:1839.
PMID: 19403903
- Hoofnagle JH.
A step forward in therapy for hepatitis C.
N Engl J Med 2009 Apr 30; 360:1899.
PMID: 19403908
- FDA NEWS RELEASE: May 23, 2011
FDA approves Incivek for hepatitis C
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm
- Jacobson IM et al
Telaprevir for previously untreated chronic hepatitis C virus
infection.
N Engl J Med 2011 Jun 23; 364:2405
PMID: 21696307
- Zeuzem S et al.
Telaprevir for retreatment of HCV infection.
N Engl J Med 2011 Jun 23; 364:2417
PMID: 21696308
- Prescriber's Letter 18(8): 2011
Victrelis (Boceprevir) and Incivek (Telaprevir) for Hepatitis C
Detail-Document#: 270802
(subscription needed) http://www.prescribersletter.com
- FDA MedWatch: Dec 19, 2012
Incivek (telaprevir) In Combination with Drugs Peginterferon
Alfa and Ribavirin (Incivek combination treatment):
Drug Safety Communication - Serious Skin Reactions.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332860.htm